Postherpetic Neuralgia News

FDA approves pregabalin extended-release for diabetic neuropathy - Healio



Market Exclusive
 
FDA approves pregabalin extended-release for diabetic neuropathy 
Healio
The FDA approved pregabalin extended-release tablets CV as a once-daily therapy for the management of pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, Pfizer announced in a press release. Pregabalin (Lyrica CR) did not ...
FDA Approves New Formula for Pregabalin MD Magazine

all 3 news articles » 


ContraVir Pharmaceuticals Announces Research Collaboration ... - Nasdaq



ContraVir Pharmaceuticals Announces Research Collaboration ... 
Nasdaq
EDISON, N.J., Oct. 17, 2017-- ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of.

and more » 


Europe Post-Herpetic Neuralgia Market and Competitive Landscape 2017 - Research and Markets - Business Wire (press release)



Europe Post-Herpetic Neuralgia Market and Competitive Landscape 2017 - Research and Markets 
Business Wire (press release)
Europe Post-Herpetic Neuralgia Market and Competitive Landscape - 2017, provides comprehensive insights into Post-Herpetic Neuralgia pipeline, epidemiology, market valuations, product sales, market forecast, product forecasts, and market shares.

 


Postherpetic Neuralgia Pipeline Insight, 2017 - Medgadget (blog)



Postherpetic Neuralgia Pipeline Insight, 2017 
Medgadget (blog)
Postherpetic Neuralgia- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding ...

and more » 


Postherpetic Neuralgia Pipeline Review 2017 - E News Access (press release)



Postherpetic Neuralgia Pipeline Review 2017 
E News Access (press release)
Postherpetic Neuralgia- Competitive Landscape, Pipeline and Market Analysis, 2017, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding ...

 


Pfizer Announces FDA Approval Of LYRICA CR Extended-release Tablets CV - Markets Insider



FiercePharma
 
Pfizer Announces FDA Approval Of LYRICA CR Extended-release Tablets CV 
Markets Insider
... announced the U.S. FDA has approved LYRICA CR (pregabalin) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy and the management of postherpetic neuralgia.
FDA approves LYRICA CR extended-release tablets CV Seeking Alpha
FDA Approves Treatment for Two Neuropathic Pain Conditions Monthly Prescribing Reference
Positive news for Pfizer's top-selling drug that could delay competition The Pharma Letter
Drug Store News 
all 7 news articles » 


Shingles vaccine, Shingrix, receives approval in Canada - Outbreak ... - Outbreak News Today



Outbreak News Today
 
Shingles vaccine, Shingrix, receives approval in Canada - Outbreak ... 
Outbreak News Today
GlaxoSmithKline announced Friday that Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged 50 years or older.

and more » 


FDA OKs Pregabalin Extended-release Once-Daily Tablets for Neuropathic Pain - Pharmacy Times



FDA OKs Pregabalin Extended-release Once-Daily Tablets for Neuropathic Pain 
Pharmacy Times
... announced that the FDA has approved pregabalin (Lyrica) extended-release tablets CV as once-daily therapy for the management of neuropathic pain associated with diabetic peripheral neuropathy (pDPN) and the management of postherpetic neuralgia ...

and more » 


Your Daily Pharma Scoop: A Seeking Alpha Interview, Spark AdCom Nod For Luxturna, Pfizer LYRICA Approval - Seeking Alpha



Seeking Alpha
 
Your Daily Pharma Scoop: A Seeking Alpha Interview, Spark AdCom Nod For Luxturna, Pfizer LYRICA Approval 
Seeking Alpha
An FDA Ad Com recommended approval for ONCE's gene therapy for biallelic RPE65-mediated inherited retinal disease. Pfizer's LYRICA CR therapy was approved for diabetic peripheral neuropathy and postherpetic neuralgia but not for Fibromyalgia.

 


FDA Approves Extended-Release Lyrica - Pain News Network



Pain News Network
 
FDA Approves Extended-Release Lyrica 
Pain News Network
Unlike the original formulation of Lyrica, which is widely prescribed to treat fibromyalgia, Lyrica CR is only approved to treat nerve pain caused by diabetic peripheral neuropathy and postherpetic neuralgia caused by shingles. But that won't stop ...